Your fact-checks will appear here
Family name
Elon Musk has made public remarks linking his ventures—notably Neuralink—and personal statements about dementia (including preferring death to living with dementia) but there is no credible evidence i...
for Alzheimer’s—chiefly plasma phosphorylated tau (p-tau) and amyloid-related ratios—have moved from research curiosities to validated clinical tools: the approved at least one plasma test in 2025–202...
Neurocept’s public profile in the available sources is limited: there are no press releases or filings about a company named “Neurocept” changing a drug-development pipeline tied to Dr. Paul Alan Cox ...
The (DxA), run by the , has directly funded scores of projects—ranging from blood-based amyloid assays and retinal scans to and biomarker studies—and has moved several into late-stage validation or co...
are now a global race: established mRNA pioneers and a growing roster of biotech firms in the , and are running more than a hundred clinical trials testing individualized neoantigen or tumor-antigen m...
A broad ecosystem of federal agencies, academic medical centers, advocacy groups, and pharmaceutical companies is actively running and sponsoring dementia trials ranging from early-phase biology and b...
Pharmaceutical industry donations and lobbying were a major, organized force in the 2024 healthcare debates, combining tens of millions in direct PAC contributions with hundreds of millions spent on l...
of anti‑amyloid monoclonal antibodies have repeatedly shown large Centiloid (CL) reductions—often taking mean group values from high baseline CL into ranges below the conventional positivity threshold...
Nine major drugmakers — Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche’s U.S. unit), Gilead Sciences, GSK (including ViiV), Merck, Novartis and Sanofi — agreed to sell selected me...
No credible 2024–2025 clinical trial announced a universal “cure” for dementia; instead, the period saw multiple trials showing modest disease‑slowing effects, new drug approvals for early Alzheimer’s...
Shareholders in targets of hostile takeovers commonly see a near-term jump in share price when an acquirer makes a public bid or a tender offer — often at a premium to the pre-bid market price — but l...
Two monoclonal anti‑amyloid drugs — lecanemab and donanemab — and a growing cohort of novel candidates (138 drugs across 182 trials) dominate the near‑term Alzheimer’s landscape, while gene therapy ta...
Neurocept is not named in the supplied search results, and available sources do not mention "Neurocept" or its phase 2 trials (available sources do not mention Neurocept) . The 2025 landscape for Alzh...
Several credible alternatives to Newself for medication-assisted weight loss exist across two broad categories: prescription GLP‑1 and related drugs (established agents and next‑generation compounds) ...
Dr. Sanjay Gupta discussed to Alzheimer’s disease in his CNN report "The Last Alzheimer’s Patient," which sources place on . Claims that he described the are present in later reporting, but there is ....